Mark Luigi Dacumos
As of January 1, 2023, the Inflation Reduction Act has capped out-of-pocket costs for insulin at $35 per month for all Medicare Part D enrollees. This significant change aims to alleviate the financial strain on beneficiaries managing diabetes, ensuring better access to this essential medication. A study published in the Journal of the American Medical Association observed an increase in insulin prescription fills among Medicare beneficiaries following the implementation of the cap, indicating improved affordability and adherence. The Facts About the $35 Insulin Copay Cap in Medicare
Add comment